Lupus (SLE)

Clinical Trials for Lupus

Clinical Trials for Lupus

General purpose: Research may investigate a variety of potential topics, including: potential causes of lupus, factors that may prevent the onset of lupus, genetic mutations associated with an increased risk of developing lupus.

The role of the body’s immune system in the development of lupus, environmental factors that may cause lupus or exacerbate its symptoms. The gender differences associated with the risk and severity of lupus, new treatments, and ways to prevent lupus from attacking various body systems and organs (such as the central nervous system, kidneys, and skin).

Clinical Trials for Lupus Continued … (Click to Open)

Join Clinical Trials for Systemic Lupus Erythematosus (SLE)

SLE Clinical Trials

What do typical clinical trials for Lupus involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use. All of these factors will depend on individual study designs, which will differ greatly between trials. However, below is a list of common procedures and data that are frequently collected during a trial for lupus:

  • Detailed personal information related to prior environmental, chemical, and biologic exposures.
  • Prior history of various diseases, such as rheumatoid arthritis, chronic fatigue syndrome, fibromyalgia, and others.
  • Blood tests to measure:
    • Antibodies, including antinuclear antibodies (ANA) panel, antithyroglobulin antibody, antithyroid microsomal antibody, complement component antibodies C3 and C4, cryoglobulins, erythrocyte sedimentation rate (ESR, or “sed rate”)
    • Complete blood count (CBC)
    • Rheumatoid factor
  • Chest x-ray
  • Kidney biopsy
  • Urine tests
  • Kidney function tests
  • Liver function tests

Examples of Lupus-related research topics:

Improved understanding of how and why lupus develops by comparing the personal histories and exposures of patients with lupus. These may include:

  • Studies to assess potential genetic influences.
  • Studies to assess environmental influences (chemical, occupational).
  • Studies to evaluate biologic factors (bacterial or viral infections; individual immune system characteristics).
  • Studies to determine new and effective medications to treat lupus.
  • Studies to observe the long-term effects of lupus on the body and mind, using imaging tests, mental health evaluations, and observation.

Suggested search terms related to Systemic Lupus Erythematosus:

“systemic lupus erythematosus treatment,” “systemic lupus erythematosus prevention,” “systemic lupus erythematosus diagnosis,” “pediatric systemic lupus erythematosus,” “systemic lupus erythematosus organ damage,” and “systemic lupus erythematosus autoimmune.”



Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: Standard of Care
Sponsor:   AstraZeneca
Recruiting


Regulatory BCells in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Diagnostic Test: blood sample
Sponsor:   Assiut University
Not yet recruiting


A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Placebo;   Drug: M2951
Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA
Recruiting


Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Belimumab
Sponsor:   GlaxoSmithKline
Active, not recruiting


Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Other: Drug free;   Drug: HCQ;   Drug: GC+HCQ
Sponsors:   Peking Union Medical College Hospital;   Xiangya Hospital of Central South University;   Shengjing Hospital;   People's Hospital of Xinjiang Uygur Autonomous Region;   Anhui Provincial Hospital
Recruiting


A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus (SLE)
Interventions:   Drug: Placebo;   Drug: Dapirolizumab pegol (DZP)
Sponsor:   UCB Biopharma S.P.R.L.
Recruiting


Walk With Ease Program For Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: "Walk With Ease"
Sponsors:   University of North Carolina, Chapel Hill;   North Carolina Translational and Clinical Sciences Institute
Recruiting


Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: ACT-334441;   Drug: Placebo
Sponsor:   Actelion
Completed


Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus


Condition:   Active Systemic Lupus Erythematosus
Interventions:   Biological: Anifrolumab;   Drug: Placebo
Sponsors:   AstraZeneca;   PRA Health Sciences
Active, not recruiting


Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus


Condition:   Active Systemic Lupus Erythematosus
Interventions:   Biological: Anifrolumab;   Drug: Placebo
Sponsors:   AstraZeneca;   PRA Health Sciences
Active, not recruiting


Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: therapeutic education
Sponsors:   University Hospital, Lille;   Région Nord-Pas de Calais, France
Recruiting


Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: MT-1303 Low dose;   Drug: MT-1303 High dose
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Completed


A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: CC-220;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting


Nelfinavir in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Nelfinavir
Sponsors:   Northwell Health;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting


Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: BENLYSTA;   Other: SLE treatment
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Recruiting


Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients


Condition:   Systemic Lupus Erythematosus
Intervention:   Behavioral: Supervised physical exercise
Sponsors:   Federal University of São Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo
Unknown status


Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Active, not recruiting


Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: MEDI-546
Sponsors:   AstraZeneca;   MedImmune LLC
Completed


A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: Placebo;   Biological: Belimumab 200 mg SC;   Drug: Standard therapy
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Completed


Aspirin Resistance in Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: aspirin and meloxicam
Sponsors:   Vanderbilt University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed


A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
Sponsors:   Human Genome Sciences Inc.;   GlaxoSmithKline
Completed


A Study of Belimumab in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
Sponsors:   Human Genome Sciences Inc.;   GlaxoSmithKline
Completed


Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Biological: Hematopoietic stem cell transplantation
Sponsor:   Northwestern University
Active, not recruiting


Monoclonal Antibody Treatment for Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: MRA 003 US
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed


Study of Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting

Refine Your Search Advanced Search